Nu Skin Enterprises reported first quarter 2025 revenue of $364.5 million, a 12.7% decrease year-over-year, but at the high end of its guidance range. The company's reported diluted earnings per share (EPS) was $2.14, significantly higher than the prior year, primarily driven by a $176.2 million pre-tax gain from the sale of Mavely.
Excluding the Mavely gain and other charges, adjusted EPS for Q1 2025 was $0.23, exceeding the company's forecast. The gross profit margin for the quarter was 67.8%, and the adjusted operating margin improved to 6.4%, reflecting ongoing cost efficiency initiatives.
The company also made substantial progress in strengthening its balance sheet, reducing outstanding debt by $155 million, achieving its lowest debt level in over a decade. For the second quarter of 2025, Nu Skin projects revenue between $355 million and $390 million, with EPS in the range of $0.20 to $0.30, while maintaining its adjusted annual guidance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.